Jane Street Group, LLC Surface Oncology, Inc. Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.61 - $1.03 $49,096 - $82,900	-80,486 Reduced 61.17%	51,083 $35,000
Q4 2022 Feb 14, 2023	BUY	$0.62 - $1.21 $81,572 - $159,198	131,569 New	131,569 $107,000
Q1 2022 May 17, 2022	SELL	$2.65 - $5.08 $37,325 - $71,551	-14,085 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$4.73 - $7.9 $102,186 - $170,671	-21,604 Reduced 60.53%	14,085 $67,000
Q3 2021 Nov 16, 2021	SELL	$5.16 - $7.98 $198,804 - $307,453	-38,528 Reduced 51.91%	35,689 $270,000
Q2 2021 Aug 16, 2021	SELL	$6.45 - $9.09 $49,639 - $69,956	-7,696 Reduced 9.4%	74,217 $554,000
Q1 2021 May 18, 2021	BUY	$7.25 - $13.82 $459,338 - $875,593	63,357 Added 341.44%	81,913 $639,000
Q4 2020 Feb 17, 2021	SELL	$6.87 - $10.48 $145,980 - $222,689	-21,249 Reduced 53.38%	18,556 $171,000
Q3 2020 Nov 17, 2020	BUY	$5.06 - $7.23 $201,413 - $287,790	39,805 New	39,805 $275,000
Q3 2019 Nov 14, 2019	SELL	$1.4 - $2.84 $40,755 - $82,675	-29,111 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$2.75 - $4.89 $80,055 - $142,352	29,111 New	29,111 $82,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.